Test Results Boost Lexaria Bioscience Corp. (NASDAQ: LEXX) Potential in Enhancing Antiviral Drugs
Lexaria Bioscience has completed a study conducted by Canada’s National Research Council for the use of its DehydraTECH IP with five drugs known to target the main protease associated with SARS-CoV-2 infection, including remdesivir The SARS-CoV-2 infection is the underlying force behind the COVID-19 pandemic that has killed millions of people during the past year and currently has begun trending toward a rising infection rate again DehydraTECH technology helps drugs gain better bioavailability through quick and effective introduction into patients’ bloodstreams using oral administration as opposed to injections The recent study results demonstrate that DehydraTECH-processed remdesivir, ebastine, bepridil, rupintrivir, and…